Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program
March 31 2008 - 6:00AM
PR Newswire (US)
Collaborators from Maxygen, Inc. Present Abstracts at Prominent HIV
Vaccine Meeting SOUTH SAN FRANCISCO, Calif., March 31
/PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. (NASDAQ:MGRM)
today announced that company researchers have co-authored with
collaborators from Maxygen, Inc. and Aldevron LLC several important
abstracts presented during the Keystone HIV Vaccines: Progress and
Prospects Symposium in Banff, Alberta. Maxygen, based in Redwood
City, CA, is using Monogram's Neutralizing Antibody Assay in its
HIV vaccine program to rapidly and accurately screen candidate
immunogens produced by gene shuffling for their ability to induce
antibodies that protect against a broad range of HIV variants. The
Maxygen HIV vaccine approach is being funded in part by grants from
the National Institutes of Health, and the U.S. Department of
Defense. "The research presented at the Keystone Symposium
underscores the value that Monogram's advanced HIV assays bring to
not only clinical practice and the development of new classes of
HIV therapeutics, but to promising vaccine programs as well," said
Chris Petropoulos, PhD, Monogram's Chief Scientific Officer and
Vice President of Research and Development, Virology. "Maxygen has
made great strides in developing vaccines against incredibly
challenging viruses. Their sophisticated development process and
use of advanced screening technologies, including the Monogram
assay, have led to the development of HIV vaccine candidates that
elicit more promising antibody responses than any other program
we've seen." Maxygen-Monogram co-authored abstracts presented at
the meeting in Banff included an oral presentation by Dr. X. Sean
Du of Maxygen, "Directed Molecular Evolution Created Genetic and
Antigenic Diversity and Improved Overall Immunogenicity of HIV-1
gp12- Immunogen," which detailed Maxygen's program to recombine and
manipulate viral envelope DNA in order to produce vaccines which
can neutralize a broad number of HIV variants. Other abstracts,
presented during poster sessions, included: -- Comparison of
Trimeric Motifs for Their Effects on Trimer Formation, Antigenicity
and Immunogenicity of a Non-cleavable JRCSF HIV-1 gp140 Immunogen;
-- ParallelaVax(TM) Technology for High-Throughput HIV-1 Vaccine
Screening; and -- Broad Survey of the Immunogenicity of HIV-1
Envelope Proteins. "Our approach to developing a successful HIV
vaccine is grounded in our ability to thoroughly and rapidly
examine how well our immunogenetic candidates produce
virus-neutralizing antibodies in animal models," said Maxygen
Director of Infectious Diseases, Robert Whalen, D.Sc. "Our
partnership with Monogram has been critical to our program's speed,
productivity and progress towards a viable HIV vaccine." About
Maxygen Maxygen is a biopharmaceutical company focused on
developing improved versions of protein drugs. The company's lead
program, MAXY-G34, is designed to be an improved version of
long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is
currently in Phase II clinical trials. Also in Maxygen's pipeline
are a new Factor VIIa product candidate for the treatment of
hemophilia and new CTLA4-Ig product candidates for the treatment of
rheumatoid arthritis. Maxygen uses its proprietary DNA shuffling
technology and extensive protein modification expertise to pursue
the creation of biosuperior proteins. http://www.maxygen.com/ About
Monogram Monogram is advancing individualized medicine by
discovering, developing and marketing innovative products to guide
and improve treatment of serious infectious diseases and cancer.
The Company's products are designed to help doctors optimize
treatment regimens for their patients that lead to better outcomes
and reduced costs. The Company's technology is also being used by
numerous biopharmaceutical companies to develop new and improved
anti-viral therapeutics and vaccines as well as targeted cancer
therapeutics. More information about the Company and its technology
can be found on its web site at http://www.monogrambio.com/.
Forward Looking Statements Certain statements in this press release
are forward-looking. These forward-looking statements include
references to the use, demand and effectiveness of our
neutralization assay technology , the size and timing of clinical
trials utilizing our products, the number of patients each year in
the U.S. who potentially could be candidates for new classes of HIV
drugs and or vaccines , expected protection provided by patents,
possible regulation of our neutralization assay and our other
products by the FDA, and activities expected to occur in connection
with the Pfizer collaboration. These forward- looking statements
are subject to risks and uncertainties and other factors, which may
cause actual results to differ materially from the anticipated
results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not
limited to: risks and uncertainties relating to the performance of
our products; the growth in revenues; the size, timing and success
or failure of any clinical trials our ability to successfully
conduct clinical studies and the results obtained from those
studies; our ability to establish reliable, high-volume operations
at commercially reasonable costs; expected reliance on a few
customers for the majority of our revenues; the annual renewal of
certain customer agreements; actual market acceptance of our
products and adoption of our technological approach and products by
pharmaceutical and biotechnology companies; our estimate of the
size of our markets; our estimates of the levels of demand for our
products; the impact of competition; the timing and ultimate size
of pharmaceutical company clinical trials; whether payers will
authorize reimbursement for our products and services and the
amount of such reimbursement that may be allowed; whether the FDA
or any other agency will decide to further regulate our products or
services, including CLIA/ Cap and the "Research Use Only" offering
of our neutralization assay; whether the draft guidance on
Multivariate Index Assays issued by FDA will be subsequently
determined to apply to our current or planned products; whether we
will encounter problems or delays in automating our processes; the
ultimate validity and enforceability of our patent applications and
patents; the possible infringement of the intellectual property of
others; whether licenses to third party technology will be
available; whether we are able to build brand loyalty and expand
revenues; restrictions on the conduct of our business imposed by
the Pfizer, Merrill Lynch and other debt agreements; the impact of
additional dilution if our convertible debt is converted to equity;
and whether we will be able to raise sufficient capital in the
future, if required. For a discussion of other factors that may
cause actual events to differ from those projected, please refer to
our most recent annual report on Form 10-K and quarterly reports on
Form 10-Q, as well as other subsequent filings with the Securities
and Exchange Commission. We do not undertake, and specifically
disclaim any obligation, to revise any forward-looking statements
to reflect the occurrence of anticipated or unanticipated events or
circumstances after the date of such statements. contacts: Alfred
G. Merriweather Jeremiah Hall Chief Financial Officer Feinstein
Kean Healthcare Tel: 650 624 4576 Tel: 415 677 2700 DATASOURCE:
Monogram Biosciences, Inc. CONTACT: Alfred G. Merriweather, Chief
Financial Officer of Monogram Biosciences, Inc., +1-650-624-4576;
Jeremiah Hall of Feinstein Kean Healthcare, +1-415-677-2700, Web
site: http://www.monogrambio.com/ http://www.maxygen.com/
Copyright
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jul 2023 to Jul 2024